METTL3/IGF2BP1轴介导的TRIM11 mRNA的m6A修饰通过降解ACSL4抑制非小细胞肺癌细胞中的铁死亡并加速恶性进展。
The METTL3/IGF2BP1 axis-mediated m6 A modification of TRIM11 mRNA suppresses ferroptosis and accelerates malignant progression in non-small cell lung cancer cells by degrading ACSL4.
作者信息
Chen Haiyang, Wang Chunmei, Dai Heyang, Shi Jian
机构信息
Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Oncology, Cangzhou People's Hospital, Cangzhou, China.
出版信息
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 16. doi: 10.1007/s00210-025-04207-7.
Tripartite motif-containing motif 11 (TRIM11) possesses a pro-tumorigenic properties in non-small cell lung cancer (NSCLC). However, the determinants that drive TRIM11 dysregulation remains to be uncovered. Effect on cell functions was assessed by detecting cell apoptosis, proliferation, viability, ferroptosis, and invasive and migratory capacities. Evaluation of in vivo activity was performed using mouse xenograft studies. Relationship between TRIM11 and METTL3 or IGF2BP1 was predicted by bioinformatics and confirmed by RNA immunoprecipitation experiments or luciferase assays. The regulation of TRIM11 in ACSL4 protein was tested by IP experiment and protein stability analysis. TRIM11 was overexpressed in NSCLC, and its high expression tended to result in poor prognosis and enhanced tumor grade. Functionally, TRIM11 disruption suppresses the malignant progression of NSCLC cells by promoting cancer cell apoptosis and ferroptosis and repressing invasion, proliferation, and migration. Mechanistically, METTL3 enhances m6A modification of TRIM11 mRNA via an IGF2BP1/m6A manner. Inhibition of METTL3 reduced TRIM11 to promote NSCLC cell ferroptosis and suppress malignant progression in vitro, as well as to mediate xenograft growth inhibition in vivo. Additionally, TRIM11 degraded ACSL4 through K63-linked ubiquitination to affect the malignant progression and ferroptosis of NSCLC cells. These findings indicate that the METTL3/IGF2BP1 axis-mediated m6A methylation of TRIM11 mRNA is responsible for NSCLC malignant progression of NSCLC. Our study is instrumental for the development of TRIM11-basic therapies for NSCLC.
含三联基序的基序11(TRIM11)在非小细胞肺癌(NSCLC)中具有促肿瘤发生特性。然而,驱动TRIM11失调的决定因素仍有待揭示。通过检测细胞凋亡、增殖、活力、铁死亡以及侵袭和迁移能力来评估对细胞功能的影响。使用小鼠异种移植研究进行体内活性评估。通过生物信息学预测TRIM11与METTL3或IGF2BP1之间的关系,并通过RNA免疫沉淀实验或荧光素酶测定进行证实。通过免疫沉淀实验和蛋白质稳定性分析测试TRIM11对ACSL4蛋白的调控。TRIM11在NSCLC中过表达,其高表达往往导致预后不良和肿瘤分级增加。在功能上,TRIM11的破坏通过促进癌细胞凋亡和铁死亡以及抑制侵袭、增殖和迁移来抑制NSCLC细胞的恶性进展。机制上,METTL3通过IGF2BP1/m6A方式增强TRIM11 mRNA的m6A修饰。抑制METTL3可降低TRIM11,从而促进NSCLC细胞铁死亡并在体外抑制恶性进展,以及在体内介导异种移植生长抑制。此外,TRIM11通过K63连接的泛素化降解ACSL4,从而影响NSCLC细胞的恶性进展和铁死亡。这些发现表明,METTL3/IGF2BP1轴介导的TRIM11 mRNA的m6A甲基化是NSCLC恶性进展的原因。我们的研究有助于开发针对NSCLC的基于TRIM11的疗法。